Last reviewed · How we verify
Moderate BP control
At a glance
| Generic name | Moderate BP control |
|---|---|
| Also known as | Enalapril-folic acid,amlodipine,hydrochlorothiazide |
| Sponsor | Second Affiliated Hospital of Nanchang University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- "Hypoxic vs. Aerobic Training in Chronic Kidney Disease (NA)
- Effect of Early Mobilization Exercises After Coronary Artery Bypass Graft (NA)
- Anesthesia Management in Endovascular Therapy for Ischemic Stroke - 2 (NA)
- Integration of Hypertension Management Into HIV Care in Nigeria (NA)
- Research on the Development and Implementation of an Exercise Rehabilitation Program for Aortic Dissection Patients After Percutaneous Intervention Based on the Behavior Change Wheel Theory (NA)
- Inspiratory Muscle Training in Hospitalized Heart Failure Patients (NA)
- Telehealth Virtual Reality Gaming on Cardiometabolic Health Among Youth With Cerebral Palsy (PHASE1)
- Effect of Electro-Acupuncture on Blood Pressure (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Moderate BP control CI brief — competitive landscape report
- Moderate BP control updates RSS · CI watch RSS
- Second Affiliated Hospital of Nanchang University portfolio CI